Compound ID | 122
Synonym(s): BT-492 | RX-334 | WQ-3034 (Baxdela)
Class: Fluoroquinolone
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Acute bacterial skin and skin structure infections; other potential indications: community-acquired bacterial pneumonia and complicated urinary tract infections |
| Propensity to select resistant mutants: | Yes |
| Institute where first reported: | Melinta Therapeutics Inc. |
| Year first mentioned: | 2009 (phase 2 trials) |
| Highest developmental phase: | Approved by FDA in 2017 |
| Development status: | Approved |
| Chemical structure(s): | |||||||||||
|
|